Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | CD40 | P25942 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14786059 | 1.00 | FOLH1 (0.39) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL14784519 | 1.00 | FOLH1 (0.39) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL16146684 | 1.00 | FOLH1 (0.39) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL14784739 | 0.96 | FOLH1 (0.41) | FOLH1GLP1RITGB3ITGA2B | |
| SCHEMBL14786042 | 0.95 | FOLH1 (0.41) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL15531610 | 0.92 | NOD1 (0.42) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL14786065 | 0.90 | FOLH1 (0.41) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL14784522 | 0.90 | FOLH1 (0.41) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL16146691 | 0.90 | FOLH1 (0.41) | FOLH1GLP1RITGB3ITGA2BNMT2 | |
| SCHEMBL14786277 | 0.90 | FOLH1 (0.41) | FOLH1GLP1RITGB3ITGA2BNMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753642-B1 | GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | claimed |
| US-10308700-B2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2019-06-04 | — | — | US | disclosed |
| US-9758560-B2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-09-12 | — | — | US | disclosed |
| US-20170145069-A1 | GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2017-05-25 | — | — | US | disclosed |
| EP-2753642-B1 | GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| US-20140303083-A1 | GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2014-10-09 | — | — | US | disclosed |
| WO-2013037690-A1 | GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145069-A1 | GLP-1 Derivatives | GLP1R, GIPR, GCG | FOLH1 545/4885GLP1R 1/4885ITGB3 2649/4885 |
| US-20140303083-A1 | GLP-1 Derivatives | GLP1R, GIPR, GCG | FOLH1 716/4885GLP1R 1/4885ITGB3 2328/4885 |
| US-10308700-B2 | GLP-1 derivatives | GLP1R, GIPR, GCG | FOLH1 594/4885GLP1R 1/4885ITGB3 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.